Early use of posaconazole in the successful treatment of rhino-orbital mucormycosis caused by Rhizopus oryzae

J Infect. 2007 Sep;55(3):e33-6. doi: 10.1016/j.jinf.2007.05.178. Epub 2007 Jul 10.

Abstract

Mucormycosis is a potentially fatal, rapidly destructive, opportunistic infection often seen in immunocompromsied individuals and patients with diabetes mellitus. We describe two patients with rhino-orbital mucormycosis caused by Rhizopus oryzae who received posaconazole within 7 days of diagnosis and in whom cure was achieved in conjunction with extensive surgical resection of diseased tissue. Posaconazole was well-tolerated. Our experience indicates that this new extended-spectrum azole antifungal agent can be used early in the course of zygomycete infection with good results.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antifungal Agents / therapeutic use*
  • Ethmoid Sinusitis / drug therapy*
  • Ethmoid Sinusitis / microbiology
  • Female
  • Humans
  • Male
  • Maxillary Sinusitis / drug therapy*
  • Maxillary Sinusitis / microbiology
  • Maxillary Sinusitis / surgery
  • Middle Aged
  • Mucormycosis / drug therapy*
  • Mucormycosis / surgery
  • Rhizopus / isolation & purification*
  • Treatment Outcome
  • Triazoles / therapeutic use*

Substances

  • Antifungal Agents
  • Triazoles
  • posaconazole